The magnitude and concentration of selling, especially by the CEO, suggests caution ahead of upcoming catalysts or earnings. Monitor for further divestitures or news that may confirm weakening confidence in near-term prospects.
BBIO drugs
BBIO drug pipeline →How the stock moved after the report
BEARISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Mar 10 $74.32entry
- T+1 · 8mo ago −3.94%α −3.84% · $71.39
- T+5 · 8mo ago −4.55%α −3.64% · $70.94
- T+20 · 7mo ago −0.24%α −0.09% · $74.14
- T+60 · 6mo ago −11.89%α −23.30% · $65.48
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BridgeBio Pharma CEO Kumar Neil sold shares worth over $1.6 million in open-market transactions, while Director Hannah Valantine exercised options and sold 8,671 shares for $624,312. The cluster is dominated by significant insider selling, with total open-market dispositions amounting to $2.27 million over seven days.
Key Financial Metrics
Key Facts
- CEO Kumar Neil sold 24,027 shares in two transactions totaling $1.64 million at prices between $68.36 and $68.48.
- Director Hannah Valantine exercised 8,671 options (intrinsic value $237,238.56) and sold all shares at $72 for $624,312 in proceeds.
- Total open-market sales in the cluster: $2.27 million.
- No open-market purchases or grants reported in the 7-day window.
- Total insider sales over the past 30 days now amount to $2.4 million.
Financial Impact
$2.27 million in net open-market selling by insiders over 7 days, representing 0.017% of the company's $13.5B market cap
Risk Factors
- Perceived lack of confidence from top leadership could pressure sentiment.
- Potential for additional insider selling if near-term catalysts are delayed or underperform.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CONTEXT: Insider Cluster Data (5 trades, 7d window) | cluster-BBIO-1773698745039 |
Track record
38 reports on BBIO
9 of 12 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 13 of 14 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $78.30 +0.17% settles Dec 11
- Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
- Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $78.30 +4.47% settles Nov 30
- Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $78.30 +10.56% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $78.30 +14.94% settles Nov 19
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $78.30 +23.70% ▲ +24.28% +27.89% vs SPY
- Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers